Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Polyvalent pneumococcal vaccine

Known as: PPSV, Pneumococcal Polysaccharide Vaccine [Chemical/Ingredient], Pneumococcal Polyvalent Vaccine 
An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
These updated guidelines of the AST IDCOP review vaccination of solid organ transplant candidates and recipients. General… Expand
Review
2019
Review
2019
Summary Background Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
2018
Review
2018
BACKGROUND The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document… Expand
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • figure 2
  • table 1
  • table 2
Review
2018
Review
2018
Streptococcus pneumoniae has a complex relationship with its obligate human host. On the one hand, the pneumococci are highly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Review
2018
Review
2018
  • K. Klugman, S. Black
  • Proceedings of the National Academy of Sciences
  • 2018
  • Corpus ID: 56173577
Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying… Expand
  • table 1
  • figure 1
  • figure 2
Review
2017
Review
2017
We performed a systematic review of the literature to establish conclusive evidence of risk factors for community-acquired… Expand
  • table 1
  • figure 1
  • table 2
  • table 6
Highly Cited
2003
Highly Cited
2003
BACKGROUND In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the… Expand
Highly Cited
2000
Highly Cited
2000
Objective. To determine the efficacy, safety and immunogenicity of the heptavalent CRM197 pneumococcal conjugate vaccine against… Expand
Highly Cited
1991
Highly Cited
1991
BACKGROUND Although the protective efficacy of pneumococcal polysaccharide vaccine has been demonstrated in randomized trials in… Expand